Cancer drug enhertu gets a shot in the arm: new Under-the-Skin version tested
NCT ID NCT07015697
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new way to give the cancer drug T-DXd (Enhertu) — as a shot under the skin instead of an IV drip. The study will enroll 76 adults with metastatic solid tumors to find the safest dose and see how well the body handles it. Researchers will also check if the drug shrinks tumors and how convenient the shot is for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trastuzumab deruxtecan (T-DXd, Enhertu) plus hyaluronidase, given as a shot under the skin
- What this could lead to
- If it works, this could offer a more convenient way to give T-DXd, potentially reducing treatment time and improving comfort for patients with certain metastatic cancers.
- What could go wrong
- This is an early Phase 1 trial with only 76 participants, so safety and effectiveness are not yet proven. The subcutaneous version may not work as well as the IV form, and side effects could be different or serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGNewport Beach, California, 92663, United States
-
Research Site
RECRUITINGAtlanta, Georgia, 30322, United States
-
Research Site
RECRUITINGLas Vegas, Nevada, 89169, United States
-
Research Site
RECRUITINGCharlotte, North Carolina, 28204, United States
-
Research Site
RECRUITINGMaumee, Ohio, 43537, United States
-
Research Site
RECRUITINGNashville, Tennessee, 37203, United States
-
Research Site
NOT_YET_RECRUITINGAsa Sul, 70200-730, Brazil
-
Research Site
NOT_YET_RECRUITINGGoiás, 74605-070, Brazil
-
Research Site
NOT_YET_RECRUITINGPorto Alegre, 90020-090, Brazil
-
Research Site
NOT_YET_RECRUITINGSanto André, 09060-650, Brazil
-
Research Site
NOT_YET_RECRUITINGSão Paulo, 01317-000, Brazil
-
Research Site
RECRUITINGRennes, France
-
Research Site
RECRUITINGChiba, Japan
-
Research Site
RECRUITINGKanagawa, 241-8515, Japan
-
Research Site
RECRUITINGTokyo, 104-0045, Japan
-
Research Site
RECRUITINGTokyo, 135-8550, Japan
-
Research Site
RECRUITINGTokyo, 142-8666, Japan
-
Research Site
RECRUITINGSeongnam-si, South Korea
-
Research Site
RECRUITINGSeoul, 03722, South Korea
-
Research Site
RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGSeoul, 3080, South Korea
-
Research Site
RECRUITINGSeoul, South Korea
-
Research Site
RECRUITINGBarcelona, Spain
-
Research Site
RECRUITINGMadrid, Spain
-
Research Site
RECRUITINGSeville, Spain
-
Research Site
RECRUITINGTaichung, Taiwan
-
Research Site
RECRUITINGTainan, Taiwan
-
Research Site
RECRUITINGTaipei, 10002, Taiwan
-
Research Site
RECRUITINGTaipei, Taiwan
-
Research Site
RECRUITINGTaoyuan City, Taiwan
-
Research Site Saint
RECRUITINGHerblain, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?
- Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
- New drug targets Hard-to-Treat breast cancer in advanced stage
- Could a simple blood test let some breast cancer patients stop treatment?
- New drug cocktail aims to outsmart resistant breast cancer